Treatment has demonstrated improvement in physical function and kept joint damage from progressing

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., November 13, 2005 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis (RA) demonstrated that more than three quarters of patients treated with Enbrel (etanercept) plus methotrexate combination therapy experienced no progression of joint damage at three years. These new results from the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study will be presented at the American College of Rheumatology's (ACR) Annual Scientific Meeting in San Diego, California.

"Rheumatoid arthritis is a chronic condition requiring long-term treatment. It is critical to provide patients with treatment options that not only reduce the signs and symptoms of the disease, but also inhibit the progression of joint damage," said Dsire van der Heijde, M.D., professor of rheumatology, University of Maastricht in the Netherlands. "The TEMPO results reinforce the benefits of ENBREL and methotrexate combination therapy and underscore the importance of effective treatment."

At three years, the majority of patients taking ENBREL and methotrexate combination therapy had no progression of joint damage. These results were significantly better than those achieved in ENBREL monotherapy and methotrexate monotherapy-treated patients. Patients receiving ENBREL monotherapy also had significantly better results than patients receiving methotrexate monotherapy. Total Sharp Score was calculated by assessing changes in joint space narrowing and bone erosion as captured by radiographic imaging.

Further, additional data presented at ACR showed that improvement in physical function was higher for the ENBREL combination group than for either therapy alone. Patients treated with ENBREL combination therapy experienced a 56 percent mean improvement in Health Assessment

Contact: Christine Cassiano, Amgen
Porter Novelli

Page: 1 2

Related medicine news :

1. Treatment for early prostate cancer associated with type of specialist seen
2. Treatment outcomes of patients with HIV and tuberculosis
3. Treatment of kidney condition requires an individualized approach
4. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
5. Treatment for homeless youth pays off in long run, study finds
6. Treatment discovered for deadly childhood disease
7. Treatment developed for patients with medically unexplained symptoms
8. Treatment drug may cause jawbone to die
9. Treatment for anorexia nervosa appears to have improved outcome
10. Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS
11. North Central Cancer Treatment Group finding ways to make treatment easier

Post Your Comments:
(Date:10/8/2015)... ... October 08, 2015 , ... Mirixa Corporation ... decade as the recognized leader in targeted patient care services, Mirixa remains dedicated ... community pharmacies available. Recent changes in the health care marketplace threaten to limit ...
(Date:10/8/2015)... ... October 08, 2015 , ... Daniel S. Herman, ... a Life Fellow by the Healthcare Information and Management Systems Society (LFHIMSS) for ... technology. The HIMSS Board of Directors advances members to this status who have ...
(Date:10/8/2015)... ... October 08, 2015 , ... Nachos, wings and beer are a ... snack selection at your weekend football gathering. , Registered dietitians from Retrofit, a ... be a football foodie while keeping your health in the game. , Have ...
(Date:10/8/2015)... ... 08, 2015 , ... Carpet One Floor & Home has just released their ... One Welcomes Your Support campaign has been raising funds to support organizations and researchers ... , Twenty-five percent of each sale will be donated to the Breast Cancer ...
(Date:10/8/2015)... ... October 08, 2015 , ... HIMSS will dig deep into one of ... and Healthcare Analytics Forum , to be held at the Westin Copley Place in ... School and David W. Bates, CIO and SVP of Brigham and Women’s Hospital, as ...
Breaking Medicine News(10 mins):
(Date:10/8/2015)... Oct. 8, 2015  A new series of videos ... by Janssen Research & Development, LLC ("Janssen") as part ... about progress in brain research, treatment options, and resources ... and communities. The new videos can be viewed on ... Mary Giliberti , J.D., Executive Director at the ...
(Date:10/8/2015)... 8, 2015 USA ... Chief Commercial Officer wird Groch für die Leitung ... verantwortlich zeichnen, die mit der Einführung von ... mit nicht muskelinvasivem Blasenkrebs nach deren voraussichtlichen Zulassung ... 1. Quartal 2016 ihren Anfang nehmen wird. --> ...
(Date:10/8/2015)... N.J. , Oct. 8, 2015 "Official Joint ... Orthopaedics heads to Cary, NC this ... 15 th anniversary and known as one of the ... is pleased to bring the Stryker Mobility Zone to SAS ... year. Bill Huffnagle , President, Reconstructive Division, ...
Breaking Medicine Technology:
Cached News: